Table 4. Prognostic analysis of disease-free survival (DFS) and overall survival (OS).
| Variables | Subgroup | DFS | OS | ||||
|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | ||||
| p | HR (95% CI) | p | p | HR (95% CI) | p | ||
| Age (yr) | < 51 vs. ≥ 51 | 0.15 | - | - | 0.86 | - | - |
| Tumor size (cm) | < 3 vs. ≥ 3 | 0.08 | 2.41 (0.80–6.67) | 0.265 | 0.06 | 1.77 (0.56–9.43) | 0.51 |
| Pathologic type | SCC vs. non-SCC | 0.04 | 2.29 (0.67–10.31) | 0.13 | 0.04 | 3.31 (1.15–7.60) | 0.045 |
| Positive pelvic nodes | No vs. yes | 0.04 | 3.7 (1.21–9.63) | 0.031 | 0.03 | 2.96 (1.78–8.64) | 0.02 |
| Positive parametrium | No vs. yes | 0.82 | - | - | 0.70 | - | - |
| Positive surgical margin | No vs. yes | 0.39 | - | - | 0.41 | - | - |
| Stromal invasion depth | < 1/3 vs. > 1/3 | 0.58 | - | - | 0.43 | - | - |
| Lymphovascular invasion | No vs. yes | 0.07 | 2.30 (0.90–7.85) | 0.182 | 0.14 | - | - |
| Treatment | Arm A vs. arm B | 0.55 | - | - | 0.38 | - | - |
Abbreviation: DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma,
a
Arm A consisted of paclitaxel plus cisplatin chemotherapy combined with radiotherapy.
b
Arm B consisted of paclitaxel plus cisplatin chemoradiotherapy followed by paclitaxel plus cisplatin consolidation chemotherapy.